Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer.

Teng LH, Wang C, Dolph M, Donnelly B, Bismar TA.

ISRN Urol. 2013 Aug 19;2013:786545. doi: 10.1155/2013/786545.


ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.

Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K, Donnelly B, Bismar TA.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):499-505. doi: 10.1097/PAI.0000000000000119.


ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Huang KC, Dolph M, Donnelly B, Bismar TA.

Clin Transl Oncol. 2014 Nov;16(11):973-9. doi: 10.1007/s12094-014-1182-x.


Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.

Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

J Hematol Oncol. 2014 Mar 7;7:21. doi: 10.1186/1756-8722-7-21.


PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.

Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA.

BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x.


ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.

Teng LH, Wang C, Bégin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA.

Urology. 2013 Aug;82(2):394-9. doi: 10.1016/j.urology.2013.03.029.


ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.

Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B.

Eur J Cancer. 2012 Mar;48(4):538-46. doi: 10.1016/j.ejca.2012.01.001.


TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.

Cancer Biol Ther. 2009 Jan;8(2):125-30.


Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.

Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhajj R.

BJU Int. 2014 Feb;113(2):309-19. doi: 10.1111/bju.12262.


ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.

Shah RB, Li J, Dhanani N, Mendrinos S.

Urol Oncol. 2016 Mar;34(3):120.e1-7. doi: 10.1016/j.urolonc.2015.10.008.


The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.

Pan X, Zhang X, Gong J, Tan J, Yin X, Tang Q, Shu K, Shen P, Zeng H, Chen N.

Prostate. 2016 Jun;76(9):823-33. doi: 10.1002/pros.23173.


Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014.


ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176.


A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.

Lippolis G, Edsjö A, Stenman UH, Bjartell A.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):145-50. doi: 10.1038/pcan.2013.7.


Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Apr;107(8):1243-9. doi: 10.1111/j.1464-410X.2010.09582.x.


Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y.

Cancer. 2015 May 1;121(9):1422-30. doi: 10.1002/cncr.29233.


Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.

Eur Urol. 2015 Oct;68(4):555-67. doi: 10.1016/j.eururo.2015.04.033.


Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563.

Items per page

Supplemental Content

Support Center